| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery (NCT02767388) | University of Nebraska | 2016-09-01 |
| Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study (NCT02877277) | Rigshospitalet, Denmark | 2016-08-08 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT02861417) | M.D. Anderson Cancer Center | 2016-08-05 |
| Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT (NCT02850822) | Nanfang Hospital, Southern Medical University | 2016-07-01 |
| Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation (NCT02750254) | Washington University School of Medicine | 2016-06-27 |
| Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant (NCT02684162) | M.D. Anderson Cancer Center | 2016-06-22 |
| Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome (NCT02737462) | CrystalGenomics, Inc. | 2016-06-01 |
| A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. (NCT02663752) | Novartis Pharmaceuticals | 2016-05-30 |
| Personalized NK Cell Therapy in CBT (NCT02727803) | M.D. Anderson Cancer Center | 2016-05-19 |
| Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT02676323) | St. Jude Children's Research Hospital | 2016-05-03 |
| Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation (NCT02719574) | Forma Therapeutics, Inc. | 2016-04-30 |
| G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT (NCT02744742) | Nanfang Hospital, Southern Medical University | 2016-04-18 |
| Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML (NCT02750995) | Daniel El Fassi | 2016-04-01 |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies (NCT02639559) | Washington University School of Medicine | 2016-03-31 |
| Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation (NCT02719821) | University of Wisconsin, Madison | 2016-03-01 |
| A Study of PLX51107 in Advanced Malignancies (NCT02683395) | Plexxikon | 2016-03-01 |
| Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (NCT02508038) | University of Wisconsin, Madison | 2016-02-12 |
| Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS (NCT02706899) | Seagen Inc. | 2016-02-01 |
| Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (NCT02494167) | Baylor College of Medicine | 2016-02-01 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (NCT02521493) | Children's Oncology Group | 2015-12-23 |
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933) | City of Hope Medical Center | 2015-12-21 |
| Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (NCT02562443) | Traws Pharma, Inc. | 2015-12-02 |
| Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome (NCT02783547) | SymBio Pharmaceuticals | 2015-12-01 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02566304) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-11-13 |
| CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies (NCT02678338) | Gilead Sciences | 2015-11-01 |
| Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation (NCT02598752) | Memorial Sloan Kettering Cancer Center | 2015-11-01 |
| Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients (NCT02431351) | Karyopharm Therapeutics Inc | 2015-11-01 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) (NCT02447666) | Celgene | 2015-09-15 |
| IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia (NCT02508324) | Weill Medical College of Cornell University | 2015-09-10 |
| Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome (NCT02530463) | M.D. Anderson Cancer Center | 2015-09-08 |
| Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant (NCT02485535) | University of Chicago | 2015-09-04 |
| Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT02543879) | Forma Therapeutics, Inc. | 2015-09-01 |
| A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies (NCT02520427) | Amgen | 2015-08-31 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (NCT02381548) | National Cancer Institute (NCI) | 2015-08-18 |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation (NCT02492737) | Agios Pharmaceuticals, Inc. | 2015-08-07 |
| Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) (NCT02464657) | M.D. Anderson Cancer Center | 2015-07-01 |
| Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation (NCT02458235) | University of California, San Francisco | 2015-06-02 |
| Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy (NCT02487069) | Nanfang Hospital, Southern Medical University | 2015-06-01 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma (NCT02424968) | Robert Lowsky | 2015-06-01 |
| Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT02396134) | City of Hope Medical Center | 2015-05-21 |
| Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (NCT02717884) | Michael Luebbert | 2015-05-01 |
| Study of DSP-7888 in Patients With Myelodysplastic Syndrome (NCT02436252) | Sumitomo Pharma Co., Ltd. | 2015-05-01 |
| A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (NCT02367456) | Pfizer | 2015-04-28 |
| Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (NCT02397720) | M.D. Anderson Cancer Center | 2015-04-07 |
| Study of Clinical Efficacy and Safety of Tosedostat in MDS (NCT02452346) | Weill Medical College of Cornell University | 2015-03-20 |
| Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (NCT02203825) | Celyad Oncology SA | 2015-03-01 |
| GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant (NCT02360111) | Memorial Sloan Kettering Cancer Center | 2015-02-01 |
| Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation (NCT02312102) | Massachusetts General Hospital | 2015-02-01 |
| Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy (NCT02226497) | Fred Hutchinson Cancer Center | 2015-01-09 |
| Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (NCT01010373) | BioMAS Ltd | 2015-01-01 |
| A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome (NCT02363491) | Opsona Therapeutics Ltd. | 2015-01-01 |
| Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (NCT02279654) | Celgene | 2014-12-17 |
| Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study (NCT02000154) | SymBio Pharmaceuticals | 2014-12-01 |
| Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (NCT02319369) | Daiichi Sankyo | 2014-11-25 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes (NCT02296242) | BioMed Valley Discoveries, Inc | 2014-11-01 |
| Blood Samples to Identify Biomarkers of Busulfan (NCT02291965) | Fred Hutchinson Cancer Center | 2014-11-01 |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations (NCT02272478) | Cardiff University | 2014-10-30 |
| Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT02250937) | M.D. Anderson Cancer Center | 2014-10-27 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant (NCT01930162) | Novartis Pharmaceuticals | 2014-10-07 |
| Occupational Status and Hematological Disease (NCT02057185) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2014-09-08 |
| Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome (NCT02262312) | Zealand University Hospital | 2014-09-01 |
| Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation (NCT02188290) | Kiadis Pharma | 2014-09-01 |
| Nonmyeloablative Haploidentical Transplant Followed by MLN9708 (NCT02169791) | Northside Hospital, Inc. | 2014-07-15 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention (NCT01951885) | Case Comprehensive Cancer Center | 2014-07-07 |
| Adoptive Transfer of Haplo-identical DLI for AML and MDS (NCT02046122) | Duke University | 2014-07-01 |
| Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (NCT02181699) | Kyowa Kirin, Inc. | 2014-06-01 |
| Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm (NCT02121418) | University of Washington | 2014-06-01 |
| Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome (NCT02117219) | MedImmune LLC | 2014-05-20 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia (NCT02115295) | M.D. Anderson Cancer Center | 2014-05-19 |
| Three Dosing Schedules of Oral Rigosertib in MDS Patients (NCT02075034) | Traws Pharma, Inc. | 2014-05-01 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (NCT02129101) | Mayo Clinic | 2014-05-01 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia (NCT01904136) | M.D. Anderson Cancer Center | 2014-04-22 |
| Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome (NCT02123836) | National University Hospital, Singapore | 2014-04-01 |
| Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant (NCT02083250) | M.D. Anderson Cancer Center | 2014-03-06 |
| Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients (NCT01951430) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2014-03-01 |
| Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (NCT01885689) | City of Hope Medical Center | 2014-02-10 |
| Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome (NCT02045654) | Samsung Medical Center | 2014-01-01 |
| Evaluation of 3 Different Doses of IV Busulfan (NCT01985061) | Institut Paoli-Calmettes | 2013-12-01 |
| Phase I Study of Milatuzumab for Graft Versus Host Disease (NCT01663766) | Gilead Sciences | 2013-12-01 |
| Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (NCT01993641) | Helsinn Healthcare SA | 2013-12-01 |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS (NCT02018926) | Mirati Therapeutics Inc. | 2013-12-01 |
| AHN-12 Biodistribution in Advanced Leukemia (NCT01207076) | Masonic Cancer Center, University of Minnesota | 2013-12-01 |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. (NCT02017457) | Carlos Graux, MD, PhD | 2013-12-01 |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) (NCT01953692) | Merck Sharp & Dohme LLC | 2013-11-22 |
| Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (NCT01634217) | Masonic Cancer Center, University of Minnesota | 2013-11-08 |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (NCT02007811) | University of Erlangen-Nürnberg Medical School | 2013-11-01 |
| Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01894477) | Fred Hutchinson Cancer Center | 2013-11-01 |
| Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome (NCT02330692) | Yonsei University | 2013-09-01 |
| Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis (NCT02065154) | University of Alabama at Birmingham | 2013-08-27 |
| Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (NCT01812252) | Fred Hutchinson Cancer Center | 2013-08-19 |
| Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study (NCT02002936) | SymBio Pharmaceuticals | 2013-08-01 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (NCT01834248) | Roswell Park Cancer Institute | 2013-07-30 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
| PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism (NCT01855698) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2013-06-01 |
| Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome (NCT01873703) | Helsinn Healthcare SA | 2013-06-01 |
| Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy (NCT01828346) | TetraLogic Pharmaceuticals | 2013-06-01 |